News
-
-
PRESS RELEASE
Premier and Concentra Meet Rising Demand in Occupational Radiology
Premier Radiology Services extends long-term contract with Concentra, the nation's largest occupational medicine provider, through 2030 to deliver fast and accurate radiology interpretations for urgent and occupational health care services -
PRESS RELEASE
MixPlaces Launches Improved Custom Map Prints Users Can Personalize in Minutes
Miami-based MixPlaces launches new and improved custom map prints, including street, topographic, and terrain map posters with customizable routes and over 20 additional features. These feature-rich maps make the perfect personalized gift for anyone -
PRESS RELEASE
Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease
Cantabio Pharmaceuticals, Inc. receives major grant from MJFF for the development of DJ-1 replacement therapy aimed at treating Parkinson's disease by increasing DJ-1 levels in patients and preventing disease progression -
PRESS RELEASE
Poba Medical and Byond Medical Form Strategic Business Partnership Bringing Together Complementary Balloon and Complex Catheter Design Expertise to Expand Premium Service
Poba Medical Inc. announces acquisition of Byond Medical, expanding capabilities in catheter assembly, balloon development, and global customer expansion -
-
PRESS RELEASE
Pampa Metals Intersects Thick Supergene Copper Enrichment Blanket and Extends Primary Cu-Au Mineralization to Depth at Piuquenes, San Juan Province, Argentina
Pampa Metals reports successful drilling for copper-gold mineralization at Piuquenes Cu-Au porphyry project. First assay results expected shortly -
-
-
PRESS RELEASE
Original-Research: Sernova Corp (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has reiterated its BUY rating and CAD 3.80 price target for Sernova Corp (ISIN: CA81732W1041) based on the company's financial statement release and business update for FY 22/23. Sernova's achievements in diabetes treatment and potential partnering deal are anticipated to drive stock performance
